-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The EMA Committee on Medicines for Human Use (CHMP) has completed its review of the monoclonal antibody regdanvimab (also known as CT-P59) for the treatment of COVID-19 .
COVID-19
After reviewing the data in the ongoing study, the results showed that Regdanvimab may reduce the hospitalization rate, shorten the recovery time of subjects by at least 3 days, and reduce the incidence of severe illness by 54%.
After reviewing the data in the ongoing study, the results showed that Regdanvimab may reduce the hospitalization rate, shorten the recovery time of subjects by at least 3 days, and reduce the incidence of severe illness by 54%.
Original source:
Original source:href="" target="_blank" rel="noopener">leave a message here